BioSpace News Archive

BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain.

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for bacterial infections, including multi-drug resistant, or MDR, bacterial infections, and rare diseases.

CadheRx Therapeutics, launched by Avalon Ventures and GSK, is discovering and developing therapeutic antibodies targeting soluble E-cadherin (sEcad) for the treatment of solid tumours including epithelial cancers.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines.

Sitari Pharmaceuticals was acquired by GlaxoSmithKline in 2019.

Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease. Using our proprietary GalXC™ and GalXC-Plus™ RNAi technologies, we discover and develop innovative RNAi-based therapies with the potential to treat both rare and more prevalent diseases.

We strive to improve the health of humans and animals - for generations. We work together with integrity and are guided by a shared purpose that defines who we are and what we do.

Headquartered in Paris, France, it is the fifth largest pharmaceutical company in the world [3] and is dedicated to the research, development, production and marketing of pharmaceutical products in seven main areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines.

Cell culture, stem cell culture, and tissue culture are core research tools necessary for basic research and the development of curative therapies. However, cells vary significantly in quality across laboratories with high rates of mislabeling, cross-contamination, and stress.

Alexion, AstraZeneca Rare Disease was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca. For more than 30 years, Alexion’s mission has been to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, supportive technologies, and healthcare services.